Last checked at 3 May 2018 17:12
3 May 2018 |
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Director/PDMR and PCA Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, announces that the Trust which manages the Deferred Share Bonus Plan ("Plan") on behalf of the employees of AMS has purchased ordinary shares of 5 pence each ("Ordinary Shares") on 30 April 2018, at a price of 306.77p on behalf of Chris Meredith, Mary Tavener, Simon Coates, Rose Guang, Eddie Johnson, Becky Walmsley, Jeff Willis, Pieter van Hoof and Cathy Tomlinson ("PDMRs") as part of the Deferred Share Bonus Plan and, under the terms of the Plan, these shares will be held in trust on their behalf.
Following these transactions the beneficial ownership of the PDMRs is as follows:
Director/PDMR | Date purchased | Shares purchased | Resultant holding | % of issued share capital |
Chris Meredith Chief Executive Officer | 30 April 2018 | 2,316 | 1,484,395 | 0.697% |
Mary Tavener Chief Financial Officer | 30 April 2018 | 586 | 1,960,277 | 0.920% |
Simon Coates PDMR | 30 April 2018 | 3,754 | 97,581 | 0.046% |
Rose Guang PDMR | 30 April 2018 | 6,670 | 42,729 | 0.020% |
Eddie Johnson PDMR | 30 April 2018 | 6,845 | 55,579 | 0.026% |
Becky Walmsley PDMR | 30 April 2018 | 2,419 | 5,888 | 0.003% |
Jeff Willis PDMR | 30 April 2018 | 4,057 | 165,396 | 0.078% |
Pieter van Hoof PDMR | 30 April 2018 | 3,867 | 127,208 | 0.060% |
Cathy Tomlinson PDMR | 30 April 2018 | 4,458 | 4,458 | 0.002% |
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Chris Meredith | ||||
2. | Reason for the notification | ||||
a) | Position/status: Director/PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transactions: · Purchase of 2,316 Ordinary Shares as part of the Deferred Share Bonus Plan on 30 April 2018 | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a | ||||
e) | Date of the transaction: 30/04/2018 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Mary Tavener | ||||
2. | Reason for the notification | ||||
a) | Position/status: Director/PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transactions: · Purchase of 586 Ordinary Shares as part of the Deferred Share Bonus Plan on 30 April 2018 | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a | ||||
e) | Date of the transaction: 30/04/2018 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Simon Coates | ||||
2. | Reason for the notification | ||||
a) | Position/status: PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transactions: · Purchase of 3,754 Ordinary Shares as part of the Deferred Share Bonus Plan on 30 April 2018 | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a | ||||
e) | Date of the transaction: 30/04/2018 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Rose Guang | ||||
2. | Reason for the notification | ||||
a) | Position/status: PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transactions: · Purchase of 6,670 Ordinary Shares as part of the Deferred Share Bonus Plan on 30 April 2018 | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a | ||||
e) | Date of the transaction: 30/04/2018 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Eddie Johnson | ||||
2. | Reason for the notification | ||||
a) | Position/status: PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transactions: · Purchase of 6,845 Ordinary Shares as part of the Deferred Share Bonus Plan on 30 April 2018 | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a | ||||
e) | Date of the transaction: 30/04/2018 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Becky Walmsley | ||||
2. | Reason for the notification | ||||
a) | Position/status: PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transactions: · Purchase of 2,419 Ordinary Shares as part of the Deferred Share Bonus Plan on 30 April 2018 | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a | ||||
e) | Date of the transaction: 30/04/2018 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Jeff Willis | ||||
2. | Reason for the notification | ||||
a) | Position/status: PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transactions: · Purchase of 4,057 Ordinary Shares as part of the Deferred Share Bonus Plan on 30 April 2018 | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a | ||||
e) | Date of the transaction: 30/04/2018 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Pieter van Hoof | ||||
2. | Reason for the notification | ||||
a) | Position/status: PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transactions: · Purchase of 3,867 Ordinary Shares as part of the Deferred Share Bonus Plan on 30 April 2018 | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a | ||||
e) | Date of the transaction: 30/04/2018 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Cathy Tomlinson | ||||
2. | Reason for the notification | ||||
a) | Position/status: PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transactions: · Purchase of 4,458 Ordinary Shares as part of the Deferred Share Bonus Plan on 30 April 2018 | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: n/a Aggregated price: n/a | ||||
e) | Date of the transaction: 30/04/2018 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
- End -
For further information, please visit www.admedsol.com or contact:
Advanced Medical Solutions Group plc | Tel: +44 (0) 1606 545508 |
Chris Meredith, Chief Executive Officer Mary Tavener, Chief Financial Officer | |
Consilium Strategic Communications | Tel: +44 (0) 20 3709 5700 |
Mary-Jane Elliott / Matthew Neal / Philippa Gardner | AMS@consilium-comms.com |
Investec Bank PLC (NOMAD & Broker) | Tel: +44 (0) 20 7597 5970 |
Daniel Adams / Patrick Robb / Gary Clarence |
About Advanced Medical Solutions Group plc - see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands; ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.
AMS's products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 75 countries via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has approximately 600 employees. For more information, please see www.admedsol.com.